3Huguet F, Leguay T, Raffoux E,et al.Pediatric-inspired therapy in adults with Phiadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study[J].J Clin Oncol,2008,27(6): 911-918.
4Stock W, La M,Sanford B,et al.What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group B study[J].Blood,2008, 112(5):1646-1654.
5Nachman JB,La M,Hunger SP, et al.Young adults with acute lymp- hoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive posfinduction treatment: A report from the children's oncology group[J].J Clin Oncol,2009,27(31): 5189-5194.
6Wetzler M,Sanford BL,Kurtzberg J,et al.Effective asparagine dep-letion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 [J].Blood,2007,109(10):4164-4167.
7Amylon MD,Shuster J,Pullen J,et al.Intensive high-dose L-aspara- ginase improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymph- oma: a Pediatric Oncology Group study[J].Leukemia,1999,13(3): 335-342.
8Mitchell L,Hoogendoor H,Giles AR, et al.Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complication in L-asparaginase induced antith- rombin I: deficiency[J].Blood,1994,83(2):386-391.
9Stock W, Douer D,DeAngelo DJ,et al.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel[J]. Leuk Lymphoma,2011,52(12):2237-2253.
10Panosyan EH,Seibel NL,Martin-Aragon S,et al.Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children' s Cancer Group Study CCG- 1961 [J]. J Pediatr Hematol Oncol,2004,26(4):217-226.
2Marinescu C, Vladareanu A M, Mihai F. Acute Lymphocytic Leukemia in Adults. Pathologic Features and Prognosis [ J ]. Rom J Intern Med, 2015, 53(1) : 31 -36.
3Kawedia J D, Rytting M E. Asparaginase in acute lympho- blastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2014, 14 Suppl: S14 -S17. DOI:10. 1016/j. clml. 2014.06.017.
4National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) [ S/OL ]. (2010-04-03) [ 2015-08- 19 ] http ://evs. nci. nih. gov/ftpl/CTCAE/CTCAE 4. 03 _ 2010-06-14_QuickReference_5 x7. pdf.
5Vrooman L M, Stevenson K E, Supko J G, et al. Postinduc- tion dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and ad- olescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study:Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 [J]. J Clin Oncol, 2013, 31 (9) : 1202 - 1210. DOI: 10. 1200/JCO. 2012.43. 2070.
6Kopecek J. Polymer-drug conjugates: origins, progress to date and future directions [ J ]. Adv Drug Deliv Rev, 2013, 65 ( 1 ) : 49 - 59. DOI : 10. 1016/j. addr. 2012,10. 014.
7Avramis V I, Sencer S, Periclou A P, et al. A randomized comparison of native Escherichia coli asparaginase and poly- ethylene glycol conjugated asparaginase for treatment of chil- dren with newly diagnosed standard-risk acute lymphoblastic leukemia : a Children' s Cancer Group study [ J ]. Blood, 2002, 99(6) : 1986 - 1994.
8Henriksen L T, Nersting J, Raja R A, et al. Cerebrospinal fluid asparagine depletion during pegylated asparaginase ther- apy in children with acute lymphoblastic leukaemia[ J]. Br JHaematol, 2014, 166 (2) : 213 - 220. DOI: 10. l111/bjh. 12865.
9Kawedia J D, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lym- phoblastie leukemia [ J ]. Blood, 2012, 119 (7) : 1658 - 1664. DOI: 10. l182/blood-2011-09-381731.
10Dinndorf P A, Gootenberg J, Cohen M H, et al. FDA drug approval summary : pegaspargase (oneaspar) for the first- line treatment of children with acute lymphoblastie leukemia (ALL)[J]. Oneologist, 2007, 12(8):991-998. DOI: 10. 1634/theoneologist. 12-8-991.
